Simon Van Belle

Summary

Affiliation: Ghent University
Country: Belgium

Publications

  1. ncbi request reprint Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey
    Peter Barrett-Lee
    Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK
    Oncologist 10:743-57. 2005
  2. doi request reprint Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals
    Erik Spaepen
    IMS Health, Brussels, Belgium
    Oncologist 13:596-607. 2008
  3. doi request reprint A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice
    S Van Belle
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    Curr Med Res Opin 28:1079-87. 2012
  4. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
  5. doi request reprint How to implement the multidisciplinary approach in prostate cancer management: the Belgian model
    Simon Van Belle
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    BJU Int 101:2-4. 2008
  6. ncbi request reprint Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy
    Simon Jean Pierre Van Belle
    University of Ghent, De Pintelaan 185, 9000 Ghent, Belgium
    Crit Rev Oncol Hematol 47:1-11. 2003
  7. doi request reprint Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study
    S Van Belle
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    Curr Med Res Opin 27:987-94. 2011
  8. ncbi request reprint Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting
    Simon Jp Van Belle
    University Hospital Ghent, Department of Medical Oncology, De Pintelaan 185, 9000 Ghent, Belgium
    Expert Opin Pharmacother 9:3261-70. 2008
  9. ncbi request reprint Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool
    Simon Van Belle
    Medical Oncology, University Hospital Ghent, De Pintelaan 185, 9000, Gent, Belgium
    Support Care Cancer 13:246-54. 2005
  10. ncbi request reprint Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy
    Bieke Van Den Bossche
    Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
    J Nucl Med 47:6-13. 2006

Detail Information

Publications38

  1. ncbi request reprint Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey
    Peter Barrett-Lee
    Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK
    Oncologist 10:743-57. 2005
    ..The ECAS data highlight the need for greater awareness of the adverse impact of anemia on cancer patients and for optimal anemia management to ensure maximal patient quality of life...
  2. doi request reprint Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals
    Erik Spaepen
    IMS Health, Brussels, Belgium
    Oncologist 13:596-607. 2008
    ..This retrospective database study compared the three currently available ESAs, epoetin alfa (EPO-A), epoetin beta (EPO-B), and darbepoetin alfa (DARB), regarding costs and outcomes...
  3. doi request reprint A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice
    S Van Belle
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    Curr Med Res Opin 28:1079-87. 2012
    ....
  4. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
    ..In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer...
  5. doi request reprint How to implement the multidisciplinary approach in prostate cancer management: the Belgian model
    Simon Van Belle
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    BJU Int 101:2-4. 2008
    ....
  6. ncbi request reprint Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy
    Simon Jean Pierre Van Belle
    University of Ghent, De Pintelaan 185, 9000 Ghent, Belgium
    Crit Rev Oncol Hematol 47:1-11. 2003
    ..The treatment of anaemia in patients with cancer undergoing chemotherapy may improve outcome in terms of both response rate to treatment and survival...
  7. doi request reprint Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study
    S Van Belle
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    Curr Med Res Opin 27:987-94. 2011
    ....
  8. ncbi request reprint Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting
    Simon Jp Van Belle
    University Hospital Ghent, Department of Medical Oncology, De Pintelaan 185, 9000 Ghent, Belgium
    Expert Opin Pharmacother 9:3261-70. 2008
    ..This paper reviews the existing literature on fosaprepitant, an intravenous neurokinin-1 anatgonist for the prevention of chemotherapy induced nausea and vomiting...
  9. ncbi request reprint Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool
    Simon Van Belle
    Medical Oncology, University Hospital Ghent, De Pintelaan 185, 9000, Gent, Belgium
    Support Care Cancer 13:246-54. 2005
    ..The ICD-10 criteria can be recommended as a diagnostic tool, whereas the FACT-F scale and the level of energy 100-mm VAS assess the intensity of fatigue, and are more suitable for follow-up of cancer-related fatigue...
  10. ncbi request reprint Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy
    Bieke Van Den Bossche
    Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
    J Nucl Med 47:6-13. 2006
    ..In vivo imaging of this molecular event by means of sequential (99m)Tc-depreotide scintigraphy could enable selection of breast cancer patients susceptible to endocrine therapy...
  11. doi request reprint Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer
    Wim P Ceelen
    Department of Surgery, University Hospital, Ghent, Belgium
    Ann Surg Oncol 19:2352-9. 2012
    ..Limited data are available on the use of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with recurrent stage III ovarian cancer...
  12. pmc Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis
    Tijl Vermassen
    Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
    Biochem Med (Zagreb) 25:439-49. 2015
    ..We therefore investigated if prostatic protein glycosylation could improve the diagnosis of prostatitis...
  13. doi request reprint Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer
    Tijl Vermassen
    Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
    Prostate 75:314-22. 2015
    ..Furthermore, sPSA is not able to discriminate between poorly-, moderately-, and well-differentiated PCa. We investigated prostatic protein glycosylation profiles as a potential PCa biomarker...
  14. ncbi request reprint Biodistribution and dosimetry of (99m)Tc-depreotide (P829) in patients suffering from breast carcinoma
    Bieke Van Den Bossche
    Division of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
    Cancer Biother Radiopharm 19:776-83. 2004
    ..This paper reports on the biodistribution and dosimetry of (99m)Tc-depreotide in patients...
  15. ncbi request reprint Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy
    Sylvie Rottey
    Division of Medical Oncology, Department of Internal Medicine, University Hospital Ghent, Ghent, Belgium
    J Nucl Med 47:1813-8. 2006
    ..Imaging results are related to clinical outcomes, as assessed with response evaluation criteria in solid tumors (RECIST)...
  16. ncbi request reprint Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869
    Simon Van Belle
    Oncologisch Centrum, Universitair Ziekenhuis, Gent, Belgium
    Cancer 94:3032-41. 2002
    ....
  17. ncbi request reprint Lobular carcinoma in situ and invasive lobular cancer of the breast
    Veronique Cocquyt
    Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    Curr Opin Obstet Gynecol 17:55-60. 2005
    ..The value of dynamic contrast-enhanced magnetic resonance imaging needs to be established for these patients...
  18. ncbi request reprint Permutation based methods for comparing quality of life between observed treatments
    Beatrijs Moerkerke
    Department of Applied Mathematics and Computer Science, UGent, Ghent University, Krijgslaan 281 S9, B 9000 Ghent, Belgium
    Stat Med 24:4055-66. 2005
    ..We apply the new methodology to analyse QOL data in an observational study of four different treatments of breast cancer. We discover that a single question captures most of the observed treatment differences in this population...
  19. ncbi request reprint Evidence for involvement of a tumor suppressor gene on 1p in malignant peripheral nerve sheath tumors
    Nadine Van Roy
    Department of Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Cancer Genet Cytogenet 143:120-4. 2003
    ..These findings together with data from the literature suggest that loss of a tumor suppressor gene located within distal 1p is implicated in the pathogenesis of MPNST...
  20. doi request reprint High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008)
    Natacha Verbeke
    Department of Medical Oncology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium
    Support Care Cancer 20:23-8. 2012
    ..The aim of this study is to provide relevant and accurate information on prevalence and treatment patterns of anaemia in Belgian cancer patients...
  21. doi request reprint Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience
    Gert De Meerleer
    Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium
    Int J Radiat Oncol Biol Phys 79:775-81. 2011
    ..To retrospectively review our experience with whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease...
  22. doi request reprint Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature
    Céline Vertriest
    Department of Obstetrics and Gynecology, Ghent University Hospital and Medical School, Ghent, Belgium
    Dig Surg 32:52-9. 2015
    ..The analysis of factors related to primary and metastatic cancer eventually influencing long-term outcomes and a review of the literature are presented in this report...
  23. doi request reprint Modern treatment for nasopharyngeal carcinoma: current status and prospects
    Sylvie Rottey
    Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
    Curr Opin Oncol 23:254-8. 2011
    ..In this article, we focus on the role of Epstein-Barr virus in the management of nasopharyngeal cancer, intensity-modulated radiotherapy, adjuvant and neoadjuvant chemotherapy, and targeted therapy...
  24. doi request reprint Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports
    Joke Marlier
    Department of Medical Oncology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium
    Endocrine 47:878-83. 2014
    ..Involvement of the pituitary axes is a severe side effect of treatment with ipilimumab with an urgent need for the correct medical intervention...
  25. doi request reprint Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer
    Tijl Vermassen
    Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
    Electrophoresis 35:1017-24. 2014
    ..001). In conclusion, N-glycosylation profiling demonstrated differences between BPH and PCa. These changes could lead to the discovery of a new biomarker for PCa...
  26. ncbi request reprint Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience
    Wim Duthoy
    Division of Radiotherapy, Ghent University Hospital, Ghent, Belgium
    Int J Radiat Oncol Biol Phys 57:1019-32. 2003
    ..With conventional techniques, kidneys and liver are the dose- and homogeneity-limiting organs. We developed a planning strategy for intensity-modulated arc therapy (IMAT) and report on the treatment plans of the first 5 treated patients...
  27. ncbi request reprint 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer
    Bieke Van Den Bossche
    Division of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
    Nucl Med Commun 25:787-92. 2004
    ....
  28. ncbi request reprint Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma
    Mireille Van Gele
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Int J Cancer 101:137-45. 2002
    ..We provid a detailed description of chromosomal translocations occurring in MCC that could be useful to direct future intensive investigation of these chromosomal regions...
  29. ncbi request reprint Cancer-related anemia: pathogenesis, prevalence and treatment
    Gunnar Birgegard
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Oncology 68:3-11. 2005
    ..These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients' quality of life and may also improve the clinical outcome...
  30. ncbi request reprint Cancer-related anemia: biological findings, clinical implications and impact on quality of life
    Jens Uwe Blohmer
    Sankt Gertrauden Krankenhaus, Berlin Wilmersdorf, Germany
    Oncology 68:12-21. 2005
    ..Systematic correction of anemia with appropriate supportive therapies prior to or during chemotherapy or radiotherapy may enhance patients' QOL...
  31. ncbi request reprint rHuEPO and treatment outcomes: the clinical experience
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncologist 9:55-69. 2004
    ....
  32. ncbi request reprint The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy
    Mark Vincent
    London Regional Cancer Program, 790 Commissioners Road E, London, ON, N6A 4L6, Canada
    Support Care Cancer 15:265-72. 2007
    ..e., a hemoglobin (Hb) of <or=100 g/l] in patients with advanced nonsmall cell lung cancer (NSCLC) receiving palliative chemotherapy is described...
  33. ncbi request reprint Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial
    Robert C F Leonard
    South West Wales Cancer Institute, Singleton Hospital, Swansea, Wales, UK
    J Natl Cancer Inst 96:1076-83. 2004
    ..We compared the benefits of a single cycle of high-dose chemotherapy and the benefits of conventional chemotherapy in patients with high-risk breast cancer in a prospective, unblinded, randomized trial...
  34. ncbi request reprint The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
    Heinz Ludwig
    Department of Medical Oncology, Wilhelminenspital, Vienna, Austria
    Eur J Cancer 40:2293-306. 2004
    ..5%). Mean haemoglobin to initiate anaemia treatment was 9.7 g/dL. Anaemia prevalence and incidence in cancer patients are high. Anaemia significantly correlates with poor performance status and many anaemic patients are not treated...
  35. ncbi request reprint A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
    Francesco Caponigro
    National Tumor Institute, Naples, Italy
    Invest New Drugs 23:85-9. 2005
    ..Phase I studies have shown that myelosuppression is the main toxicity of sabarubicin, while its cumulative cardiotoxicity is mild...
  36. ncbi request reprint Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid
    Kjell A Mortier
    Laboratory of Toxicology, Ghent University, Harelbekestraat 72, B 9000 Ghent, Belgium
    Anal Chem 77:4677-83. 2005
    ..Accuracy varied from 91.3 to 103.6%, and imprecision did not exceed 12.7% for all analytes in plasma and oral fluid. In conclusion, a sensitive and robust method was obtained, which fulfilled all validation criteria...
  37. ncbi request reprint Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel...
  38. ncbi request reprint Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
    Peter Nygren
    Department of Oncology, Radiology, and Clinical Immunology, Uppsala University Hosipital, Uppsala, Sweden
    Cancer Chemother Pharmacol 55:609-16. 2005
    ..In this study we examined the potential for aprepitant to affect the pharmacokinetics and toxicity of intravenously administered docetaxel, a chemotherapeutic agent that is primarily metabolized by CYP3A4...